Abraham Schneider, DDS, PhD
Dental Degree
DDS, Cayetano Heredia Peruvian University, Lima, Peru 1989
Residency
University of Connecticut Health Center, 1995, Periodontics
PhD
University of Michigan, 2005, Oral Health Sciences
Certification
Eastman Dental Center, 1993, Advanced Education in General Dentistry
Postdoctoral Fellowship
National Institute of Dental and Craniofacial Research, 2005 - 2007
Dr. Abraham Schneider is the George C. Paffenbarger Alumni - Endowed Chair in Dental Research, tenured Professor and Associate Dean for Research at The Ohio State University College of Dentistry. Prior to joining the university in November 2025, he served as Chair of the Department of Oncology and Diagnostic Sciences and Director of the Dental Biomedical Sciences PhD Program at the University of Maryland, Baltimore (UMB) School of Dentistry. He joined UMB in 2005 as faculty member in the Department of Oncology and Diagnostic Sciences. Dr. Schneider received his dental degree from the Cayetano Heredia Peruvian University in Lima, Peru. He then completed an Advanced Education in General Dentistry (AEGD) program at the Eastman Dental Center in Rochester, NY, a residency in Periodontics at the University of Connecticut Health Center in Farmington, CT, and a PhD in Oral Health Sciences at the University of Michigan in Ann Arbor, MI. He conducted postdoctoral research at the National Institute for Dental and Craniofacial Research (NIDCR) in Bethesda, MD.
Potential of drug repurposing for dental and craniofacial applications, including bone regeneration and dentin repair.
Research in the Schneider laboratory centers on the potential of drug repurposing for dental and craniofacial applications. Currently, we are investigating the application of the first-line antidiabetic drug metformin within locally delivered formulations to potentiate mineralized tissue regeneration and repair including (a) dental pulp stem cell (DPSC)-based craniofacial bone regeneration and (b) dentin repair. We are primarily interested on the key cellular and molecular determinants underlying the responses to metformin in DPSCs to support a pro-regenerative tissue microenvironment.
R01 NIDCR 8/1/2024 - 4/30/2029 Novel tunable metformin-releasing injectable scaffolds to enhance dental pulp stem cell-based craniofacial bone regeneration
